Cannabis-Use-Disorder - Pipeline Insight, 2024

This “Cannabis-Use-Disorder- Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cannabis-Use-Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cannabis-Use-Disorder Understanding

Cannabis-Use-Disorder: Overview

The term ‘cannabis’ refers to any product from plants of the cannabis genus, including marijuana and hashish, which are used primarily for their reinforcing effects. The main psychoactive compound in cannabis is ?9-tetrahydrocannabinol (THC); however, more than 100 other cannabinoids have been identified. Cannabis is considered by the Food and Drug Administration as a Schedule I drug. Cannabis abuse is a term describing the continued use of cannabis despite impairment in psychological, physical, or social functioning. Researchers know that prolonged and heavy cannabis use can alter brain circuitry. However, the specific pathophysiological mechanisms are yet unclear. Unlike synthetic substances and alcohol, cannabis is a more complex drug. Consumption or inhalation of the botanical exposes the user to hundreds of compounds, including cannabinoids (e.g., THC and cannabidiol) and non-cannabinoids (e.g., terpenes and flavonoids), many of which are bioactive compounds. While it is popularly reported that there are no withdrawal effects from cannabis, there is evidence for withdrawal symptoms in CUD that are comparable to nicotine withdrawal in magnitude and consequences. Less common physical symptoms include stomach pain, shakiness and sweating. Withdrawal symptoms are nevertheless closely linked to relapse: most abstinent individuals experiencing withdrawal symptoms will take the drug to alleviate symptoms, thereby perpetuating cannabis use. The withdrawal syndrome is also important in medicinal cannabis use. Notably, cannabis withdrawal symptoms overlap with mood and anxiety disorder symptoms. Prevalence rates for cannabis use disorder (CUD) range from 2.9% up to 19% - with approximately 13 million individuals worldwide meeting criteria. Other comorbid conditions are common in CUD; in particular, high rates of depression, anxiety, substance use and personality disorders are consistently associated with CUD.

Cannabis-Use-Disorder- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cannabis-Use-Disorder pipeline landscape is provided which includes the disease overview and Cannabis-Use-Disorder treatment guidelines. The assessment part of the report embraces, in depth Cannabis-Use-Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cannabis-Use-Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Cannabis-Use-Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Cannabis-Use-Disorder.

Cannabis-Use-Disorder Emerging Drugs Chapters

This segment of the Cannabis-Use-Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cannabis-Use-Disorder Emerging Drugs

AEF 0117: Aelis FarmaAEF0117 is a new molecular entity (NME) developed by Aelis Farma to treat the harmful effects of excessive cannabis use. AEF0117's major characteristics includes: High potency in inhibiting the effects of cannabis’ active ingredient, THC, in several animal species including primates without side effects on normal behavior, favorable ADMET profile, with good oral absorption, brain access, long half-life and no toxic or adverse effects identified to date (Therapeutic index >13,000), good pharmacokinetic, safety and efficacy profile in healthy volunteers and cannabis addicts. The clinical development of AEF0117 is supported by grants from NIDA-NIH (National Institute on Drug Abuse of the National Institute of Health, US).

ANEB-001: Anebulo PharmaceuticalsANEB-001 is being developed with the intent to quickly and effectively reverse the negative effects of cannabinoid intoxication within one hour of administration. ANEB-001is a competitive CB1 antagonist with a high affinity for the human CB1 receptor. There is currently no medical treatment approved to alleviate the symptoms of cannabinoid intoxication. ANEB-001 is a potent, small molecule cannabinoid receptor antagonist, to address the unmet medical need for a specific antidote for cannabinoid intoxication. Based on Phase 1a and 1b data, Anebulo Pharmaceuticals believed ANEB-001 will reverse the symptoms of cannabinoid intoxication within 1 hour of administration.

NFL-201: NFL BiosciencesNFL-201 is a future drug candidate for treating dependence on cannabis, which is frequently consumed alongside tobacco, as well as alcohol. The psychoactive molecule THC and CBD will be removed from the extract during the manufacturing process, in the same way that nicotine is removed from the tobacco leaf extract for NFL-101.

Cannabis-Use-Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Cannabis-Use-Disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cannabis-Use-Disorder

There are approx. 5+ key companies which are developing the therapies for Cannabis-Use-Disorder. The companies which have their Cannabis-Use-Disorder drug candidates in the most advanced stage, i.e. phase II include, Aelis Farma.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cannabis-Use-Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cannabis-Use-Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cannabis-Use-Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cannabis-Use-Disorder drugs.

Cannabis-Use-Disorder Report Insights

• Cannabis-Use-Disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cannabis-Use-Disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cannabis-Use-Disorder drugs?
• How many Cannabis-Use-Disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cannabis-Use-Disorder?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cannabis-Use-Disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cannabis-Use-Disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Aelis Farma
• Anebulo Pharmaceuticals
• NFL Biosciences
• Opiant Pharmaceuticals
• Embera

Key Products

• AEF0117
• OPNT004
• NFL-201
• ANEB-001
• EMB-001

This product will be delivered within 2 business days.